Objective: Peripheral fat loss and visceral fat gain have been reported in HIV infection. There
are limited data on long-term change in adipose tissue in HIV-infected patients vs. controls …

In this cross-sectional study, we sought to determine whether gene expression of
macrophage markers and inflammatory chemokines in lipoatrophic subcutaneous …

The lipodystrophy syndrome and associated metabolic alterations are the most prevalent
adverse effects in HIV-infected patients taking highly active anti-retroviral therapy (HAART) …

Objective and design: The present study aims at evaluating the influence of genetic
polymorphisms on antiretroviral therapy (ART)-associated lipodystrophy. We included in the …

Objective To assess whether changes in antiretroviral drugs other than thymidine
nucleoside reverse transcriptase inhibitors (NRTI) may have a body fat impact in HIV …

Background The relationship between the subjective diagnosis of lipoatrophy and the
objective amount of limb fat loss in HIV‐infected adults is unclear. Methods Using Medline …

Background Human immunodeficiency virus (HIV)-associated lipodystrophy is a syndrome
that occurs primarily in individuals who are being treated with highly active antiretroviral …

Background No biological marker has been identified that predicts the development of
lipodystrophy (LD). We investigated whether metabolic and body composition parameters …

Highly active antiretroviral therapy (HAART) for HIV-infection is associated with
lipodystrophy, insulin resistance, increased prevalence of disturbances in glucose tolerance …

Lipodystrophy has been extensively described in patients with advanced disease on long-
term protease inhibitor therapy. We report lipodystrophy occurring in 20% of HIV-infected …